Jack A. Roth

59.2k total citations · 7 hit papers
661 papers, 36.5k citations indexed

About

Jack A. Roth is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Jack A. Roth has authored 661 papers receiving a total of 36.5k indexed citations (citations by other indexed papers that have themselves been cited), including 275 papers in Pulmonary and Respiratory Medicine, 227 papers in Molecular Biology and 219 papers in Oncology. Recurrent topics in Jack A. Roth's work include Lung Cancer Treatments and Mutations (115 papers), Lung Cancer Diagnosis and Treatment (101 papers) and Virus-based gene therapy research (97 papers). Jack A. Roth is often cited by papers focused on Lung Cancer Treatments and Mutations (115 papers), Lung Cancer Diagnosis and Treatment (101 papers) and Virus-based gene therapy research (97 papers). Jack A. Roth collaborates with scholars based in United States, Japan and China. Jack A. Roth's co-authors include Stephen G. Swisher, Joe B. Putnam, Garrett L. Walsh, Tapas Mukhopadhyay, John D. Minna, Ara A. Vaporciyan, Arlene M. Correa, Jaffer A. Ajani, Bingliang Fang and Lin Ji and has published in prestigious journals such as New England Journal of Medicine, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Jack A. Roth

647 papers receiving 35.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers

2005 1.9k citations Jack A. Roth, Adi F. Gazdar et al. profile →
Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal Cancer

1998 997 citations Jack A. Roth et al. profile →
BRAF and RAS mutations in human lung cancer and melanoma.

2002 841 citations John D. Minna, Jack A. Roth et al. PubMed profile →
A Randomized Trial Comparing Perioperative Chemotherapy and Surgery With Surgery Alone in Resectable Stage IIIA Non-Small-Cell Lung Cancer

1994 804 citations Jack A. Roth et al. profile →
Wild-Type Human p53 and a Temperature-Sensitive Mutant Induce Fas/APO-1 Expression

1995 615 citations Jack A. Roth et al. profile →
Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein

1998 519 citations Jack A. Roth profile →
Gene Therapy for Cancer: What Have We Done and Where Are We Going?

1997 507 citations Jack A. Roth et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Jack A. Roth	16.3k	13.4k	12.9k	8.3k	4.6k	661	36.5k
Waun Ki Hong	8.1k 0.5×	16.8k 1.3×	12.7k 1.0×	4.3k 0.5×	3.8k 0.8×	512	34.0k
Guido Sauter	10.0k 0.6×	17.6k 1.3×	13.6k 1.1×	5.2k 0.6×	3.8k 0.8×	600	35.0k
Daniel D. Von Hoff	6.7k 0.4×	19.7k 1.5×	23.6k 1.8×	4.1k 0.5×	2.8k 0.6×	821	44.9k
James L. Abbruzzese	8.6k 0.5×	16.1k 1.2×	25.9k 2.0×	7.9k 1.0×	1.9k 0.4×	513	43.3k
Scott M. Lippman	10.6k 0.7×	13.5k 1.0×	12.8k 1.0×	4.8k 0.6×	4.3k 0.9×	528	37.2k
Angelo M. De Marzo	14.1k 0.9×	16.9k 1.3×	8.9k 0.7×	3.5k 0.4×	3.3k 0.7×	443	35.0k
Ming‐Sound Tsao	13.8k 0.8×	16.5k 1.2×	15.3k 1.2×	3.0k 0.4×	1.7k 0.4×	653	37.2k
Nicholas J. Vogelzang	22.7k 1.4×	8.4k 0.6×	17.2k 1.3×	10.1k 1.2×	1.4k 0.3×	701	41.8k
Everett E. Vokes	15.5k 1.0×	9.6k 0.7×	19.2k 1.5×	7.6k 0.9×	1.3k 0.3×	774	36.3k
Adel K. El‐Naggar	5.7k 0.3×	12.0k 0.9×	16.8k 1.3×	11.9k 1.4×	2.2k 0.5×	679	36.4k

Countries citing papers authored by Jack A. Roth

Since Specialization

Citations

This map shows the geographic impact of Jack A. Roth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jack A. Roth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jack A. Roth more than expected).

Fields of papers citing papers by Jack A. Roth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jack A. Roth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jack A. Roth. The network helps show where Jack A. Roth may publish in the future.

Co-authorship network of co-authors of Jack A. Roth

This figure shows the co-authorship network connecting the top 25 collaborators of Jack A. Roth. A scholar is included among the top collaborators of Jack A. Roth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jack A. Roth. Jack A. Roth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sitthideatphaiboon, Piyada, Ana Galan Cobo, Marcelo V. Negrão, et al.. (2020). STK11 /LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition. Clinical Cancer Research. 27(6). 1720–1733. 57 indexed citations

Meraz, Ismail M., Mourad Majidi, Feng Meng, et al.. (2019). An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses. Cancer Immunology Research. 7(8). 1267–1279. 108 indexed citations

Meraz, Ismail M., Mourad Majidi, Xiaobo Cao, et al.. (2018). TUSC2 Immunogene Therapy Synergizes with Anti–PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras -Mutant Mouse Lung Cancer Models. Cancer Immunology Research. 6(2). 163–177. 42 indexed citations

Xie, Yang, Wei Lü, Shidan Wang, et al.. (2018). Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer. Clinical Cancer Research. 25(1). 150–157. 13 indexed citations

Yan, Xiang, Xiaoshan Zhang, Li Wang, et al.. (2018). Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis. Cancer Research. 79(1). 125–132. 62 indexed citations

Nelson, David B., David C. Rice, Jiangong Niu, et al.. (2017). Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis. Journal of Clinical Oncology. 35(29). 3354–3362. 58 indexed citations

Lin, Jing, Kai Xu, Jun Wei, et al.. (2016). MicroRNA-124 Suppresses Tumor Cell Proliferation and Invasion by Targeting CD164 Signaling Pathway in Non-Small Cell Lung Cancer. PubMed. 2(1). 31 indexed citations

Melkonian, Stephanie C., et al.. (2016). Glycemic Index, Glycemic Load, and Lung Cancer Risk in Non-Hispanic Whites. Cancer Epidemiology Biomarkers & Prevention. 25(3). 532–539. 31 indexed citations

Lu, Haibo, Li Wang, Wen Gao, et al.. (2013). IGFBP2/FAK Pathway Is Causally Associated with Dasatinib Resistance in Non–Small Cell Lung Cancer Cells. Molecular Cancer Therapeutics. 12(12). 2864–2873. 52 indexed citations

10.

Wang, Yan, Jian Gu, Jack A. Roth, et al.. (2013). Pathway-Based Serum microRNA Profiling and Survival in Patients with Advanced Stage Non–Small Cell Lung Cancer. Cancer Research. 73(15). 4801–4809. 71 indexed citations

11.

Xia, Pu, Jack A. Roth, Michelle A.T. Hildebrandt, et al.. (2013). MicroRNA-Related Genetic Variants Associated with Clinical Outcomes in Early-Stage Non–Small Cell Lung Cancer Patients. Cancer Research. 73(6). 1867–1875. 35 indexed citations

12.

Xia, Pu, Yuanqing Ye, Margaret R. Spitz, et al.. (2012). Predictors of Survival in Never-Smokers with Non–Small Cell Lung Cancer: A Large-Scale, Two-Phase Genetic Study. Clinical Cancer Research. 18(21). 5983–5991. 11 indexed citations

13.

Dai, Bingbing, Jieru Meng, Michael Peyton, et al.. (2011). STAT3 Mediates Resistance to MEK Inhibitor through MicroRNA miR-17. Cancer Research. 71(10). 3658–3668. 80 indexed citations

14.

Xie, Yang, Guanghua Xiao, Kevin R. Coombes, et al.. (2011). Robust Gene Expression Signature from Formalin-Fixed Paraffin-Embedded Samples Predicts Prognosis of Non–Small-Cell Lung Cancer Patients. Clinical Cancer Research. 17(17). 5705–5714. 130 indexed citations

15.

Katz, Ruth L., Abha Khanna, Tanweer M. Zaidi, et al.. (2010). Genetically Abnormal Circulating Cells in Lung Cancer Patients: An Antigen-Independent Fluorescence In situ Hybridization–Based Case-Control Study. Clinical Cancer Research. 16(15). 3976–3987. 37 indexed citations

16.

Shivapurkar, Narayan, Victor Stastny, Naoki Okumura, et al.. (2008). Cytoglobin, the Newest Member of the Globin Family, Functions as a Tumor Suppressor Gene. Cancer Research. 68(18). 7448–7456. 91 indexed citations

17.

Pataer, Abujiang, Wenxian Hu, Xiaolin Lü, et al.. (2008). Adenoviral endoplasmic reticulum–targeted mda-7/interleukin-24 vector enhances human cancer cell killing. Molecular Cancer Therapeutics. 7(8). 2528–2535. 17 indexed citations

18.

Prudkin, Ludmila, Carmen Behrens, Diane D. Liu, et al.. (2008). Loss and Reduction of Fus1 Protein Expression is a Frequent Phenomenon in the Pathogenesis of Lung Cancer. Clinical Cancer Research. 14(1). 41–47. 68 indexed citations

19.

Jayachandran, Gitanjali, Kai Xu, Luc Girard, et al.. (2007). Fragile Histidine Triad–Mediated Tumor Suppression of Lung Cancer by Targeting Multiple Components of the Ras/Rho GTPase Molecular Switch. Cancer Research. 67(21). 10379–10388. 23 indexed citations

20.

Elayadi, Anissa N., Kausar N. Samli, Ludmila Prudkin, et al.. (2007). A Peptide Selected by Biopanning Identifies the Integrin αvβ6 as a Prognostic Biomarker for Nonsmall Cell Lung Cancer. Cancer Research. 67(12). 5889–5895. 162 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact